CLDI - Calidi Biotherapeutics, Inc.
Close
1.5
0.010 0.667%
Share volume: 10,098
Last Updated: Thu 26 Dec 2024 07:30:40 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.32%
PREVIOUS CLOSE
CHG
CHG%
$1.49
0.01
0.67%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
6.62%
1 Month
-28.22%
3 Months
26.09%
6 Months
-22.87%
1 Year
-91.32%
2 Year
-98.55%
Key data
Stock price
$1.50
DAY RANGE
$1.40 - $1.52
52 WEEK RANGE
$0.90 - $16.80
52 WEEK CHANGE
-$90.00
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Allan J. Camaisa
Region: US
Website: www.calidibio.com
Employees: 38
IPO year: -
Issue type: Common Stock
Market: NYSE American
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: www.calidibio.com
Employees: 38
IPO year: -
Issue type: Common Stock
Market: NYSE American
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. The company was founded in 2014 and is based in San Diego, California.
Recent news